Smitha S Krishnamurthi MD

Hematology•Cleveland, OH

Assistant Professor, Medicine, Case Western Reserve University School of Medicine

Join to View Full Profile

11100 Euclid AveCleveland, OH 44106
Phone+1 216-844-8500

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
University of Pennsylvania Health SystemResidency, Internal Medicine, 1993 - 1996
Perelman School of Medicine at the University of PennsylvaniaClass of 1993

Certifications & Licensure

OH State Medical License 2000 - 2026
MD State Medical License 1996 - 2001
PA State Medical License 1994 - 1996
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013

Clinical Trials

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 1
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer Start of enrollment: 2006 Mar 01
Terminated
Phase 1
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors Start of enrollment: 2007 Mar 01
Completed
Phase 1
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2006 Oct 23
Completed
Phase 2
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 1
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Start of enrollment: 2010 Oct 01
Terminated
Phase 2
Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer Start of enrollment: 2012 Apr 01
Withdrawn
Early Phase 1
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Start of enrollment: 2011 Oct 01
Completed
Phase 2
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Start of enrollment: 2013 Feb 21
Completed
Phase 2
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety Start of enrollment: 2014 Feb 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Bridging therapy with histotripsy prior to liver transplantation for hepatocellular carcinoma: a first case report.
Melis Uysal, Chase J Wehrle, Christopher Coppa, Suneel Kamath, Smitha Krishnamurthi
Experimental Hematology & Oncology. 2025-02-25
Is Early, Postinduction Restaging of Rectal Cancer Undergoing Total Neoadjuvant Therapy Associated With Ultimate Treatment Response?
William C Chapman Jr, Emre Gorgun, Sumeyye Yilmaz, David R Rosen, Michael A Valente
Diseases of the Colon and Rectum. 2025-02-01
1 citations
What Predicts Complete Response to Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer?
Sumeyye Yilmaz, David Liska, Madison L Conces, Naz Tursun, Doua Elamin
Diseases of the Colon and Rectum. 2025-01-01

Other

Enterotoxicity of chemotherapeutic agents
Krishnamurthi SS
http://www.uptodate.com/contents/enterotoxicity-of-chemotherapeutic-agents
UpToDate, Wolters Kluwer Health - 2013-02-12

Press Mentions

Local Man Shares Colorectal Cancer Story as Diagnosis Increasing in Adults Younger Than 50March 15th, 2021
New Immunotherapy Agent Reduces Disease Progression Risk in Gastric CancersJune 14th, 2016
Capecitabine Combo Improves Survival in Resected Pancreatic CancerJune 3rd, 2016
Join now to see all